Introduction
Mmor histocompatibility antigens (mHag) are products of genetic loci responsible for graft rejection As the MHC encoded major Η Systems, the mmor Η antigens have lmportant biological functions besides their role in organ and bone marrow transplantation (BMT) Their latter charactenstic, however, was first disclosed Both types of transplantation antigens were described by Snell (1) and dissevered from one another on the basis of their respective power in murme tumor graft rejection modeis (2) Skm-graftmg expenments m the mouse demonstrated the presence of a large number of histocompatibility antigens coded for by multiple loci scattered all over the genome They showed distmguishable patterns in ehcltmg allogeneic reaction, skm graftmg over a multiple mmor Η barrier demonstrated a graft rejection time comparable to those that differed only at H-2 (2-4)
In human transplantation, donors and recipients are routmely screened for Identification of the major Η System, therefore, graft-versus-host disease (GVHD) and rejection may be caused by the dispanty of the products of the mmor Η Systems, ι e histocompatibility antigens other than those coded for by the MHC The descnption by Zinkernagel & Doherty (5) of the classical lmmunological phenomenon of the MHC-restricted rec ogmtion of viral antigens by Τ cells appeared also to apply to the recogmtion of non-MHC alloanügens In the seventies, murme (6, 7) and human (8, 9) mHag were defined in vitro by MHC-restricted Τ cells
In man, mHag studies have predommantly been performed m the HLA-identical BMT settmg The efforts of several investigators have led to the Identification of a relatively small number of mHag Both cytotoxic Τ cells (CTLs) and T-helper (Th) cells recognizmg mHag m a classical MHC-restricted fashion were described MHC molecules serve as templales (10) for peptides derived from miracellularly processed protems (11, 12) This knowledge was essenüal for the prediction that mHag are naturally processed fragments of intracelliilar protems that associate with MHC molecules (13, 14) Indeed, this supposition was recently venfied both for murme (15) and human mHag (16) This review summarizes our current knowledge of the impact of mHag on the outcome of BMT and discusses the putative chnical apphcabihties now that biochemical ldentification of mHag IS possible
The male-specific mHag H-Y -cellular recogmtion
The mvolvement of H-Y (at that time called Y-factor) m homograft rejection had been postulated by Eichwald & Shmser (17) in 1955 The term H-Y antigen was mtroduced by Billmgham & Silvers (18) smce the Y-factor is a transplantation antigen, determmed by a histocompatibihly gene, comparable in all respects to the antigens responsible for homograft rejection
In vitro immune response agamst the human-male specific histocompatibility antigen H-Y was detected in a multi-transfused female aplastic anemia patient She received, after antithymocyte globulm (ATG) pretreatment, a bone marrow (BM) graft, donated by her HLA-genotypically identical male sibling In vitro analysis of the post-transplant penpheral blood lymphocytes (PBLs) of the female patient (HLA phenotype HLA-A2, A2, B44, B60, Cw3, Cw5, DR4, DRw6) showed unambiguously strong CTL responses specific for male HLA-A2-positive target cells (8, 9) Whether the Η-Y-speciflc CTLs actually mediated the allograft rejection, we do not know It must be , remarked, however, that most probably the female patient, who was suffermg from severe aplastic anemia, had been sensitized to the H-Y antigen prior to transplantation through multiple blood transfusions and pregnancies Interestmgly, the anü-H-Y response m the latter patient appeared broader than the HLA-A2-restncted CD8 CTL clones We isolated two CD4 cytotoxic and proliferative H-Y-specific clones one restricted via HLA-A2 and the other one recogmzed an H-Y T-cell epitope in association with HLA-B60 (Table 1 ) (19) Although m our first case we could not formally prove that the H-Y-specific CTLs actually mediated the rejection of the male BM allograft, some years ago we were confronted with a case with a fatal outcome m which anti-H-Y CTLs were most probably mainly responsible for BM graft failure It concerned a multi-transfused female patient suffermg from myelodysplasia after treatment for Hodgkm's disease In vitro analysis prior to BMT demonstrated the presence of HLA-Al -restricted anti-H-Y CTLs (Table 1 UPN 4) Smce the father appeared to be the only HLA-compatible related donor, he was the obvious choice (despite the presence of the patient's pretransplant anti-H-Y CTLs) Notwithstandmg intensive pretransplant immunosuppressive treatment, there was no recovery of the BM hematopoietic function (20) In view of the latter case, expression of mHag on hematopoieüc stem cells (HPCs) might be lelevant in presensitized patients receivmg an mHag-positive T-celldepleted marrow graft For that purpose, the expression of the male-specific antigen H-Y was studied for lts expression on HPCs It became clear that, indeed, H-Y is expressed on CFU-GEMM, CFU-GM and BFU-E (21) The assumption that H-Y sensitization can readily occur followmg blood transfusion and organ transplanlation is based on our subsequenl observations As shown in Table 1 , PBLs derived from three additional cases showed, after in vitro restimulation with HLA-identical male cells, exactly the same phenomenon, namely HLA-restricted (-AI, -A2 and/or -B7) anti-H-Y CTL acüvity In one patient (Table 1 UPN 5) , the H-Y-speafic HLA.-B7-restricted cytotoxiclty was delecled shortly after a kidney donated by an HLA-identical male siblmg acutely rejected (unpubhshed observation) In circumstances similar to ours, other mvestigator;, have also 126 lmmunological Reviews 157/1997
Goulmy Minor Η antigens useful tools for marrow transplantaton (41) In view of the latter notion, we mvestigated whether the mHag are evolutionarily conserved between human and non-human primates Indeed, human HA-1, HA-2 and H-Y peptides can be recogmzed on the cell surface of non-human primate cells transfected with human class I genes by our human HA-1-, HA-2-and H-Y-specific class I-restricted CTL clones Furthermore, the mH peptides could be eluted from HLA-A2 1 molecules expressed on the transfected nonhuman primate cells This implies that the human mH peptides have been conserved for at least 3 5 milhon years (42) Indeed, concurrent with our latter study, Kent-First et al (43) demonstrated the expression of the SMCY gene m early primate development Moreover, the SMCY gene was shown to be widely expressed (41, 43) This is in concordance with our previous mHag H-Y tissue distribution studies, wherem we demonstrated ubiquitous expression of the human mHag H-Y (44) The precise function of the SMCY gene is still not known It is expressed very early m embryogenesis (41) SMCY is homologous to SMCX (located on the X chromosome) at the ammo acid level at 84 4% (43) SMCY (and SMCX) protems share sigmficant sequence homology to retinoblastoma-bmding protein suggestmg that the SMCY gene may Code for a transcription factor (43) The male-specific mHag H-Y -chnical relevance It has been suggested that GVHD is more frequent in male recipients of marrow from female donors (45) This effect was seen primarily with female donors who had been pregnant or had received a transfusion (45) Indeed, the above-described H-Y responses (Table 1) were preceded by thorough in vivo sensitization events However, a mismatch for H-Y between donor Besides the Y-hnked mHag, one can assume that, as m the mouse, the human genome has an abundance of mH lociencodmg protems that generate mH peptides that are either processed via the MHC c'ass I pathway or presented m the context of MHC class II Boch mHag-specific class I-restricted CTLs and class II-restricted Th cells are probably mediating GVHD m HLA-matched BM transplants In the mouse, a vanety of studies has been carried out to explore the identity and function of cells responsible for GVH reacüons After the initial expenments of Boak & Wilson (49) , who showed that allogeneic lymphoid cell populations devoid of donor Τ cells do not mduce GVHD, and those of Korngold & Sprent (50) , who showed that, by removing mature Τ cells from the marrow, lethal GVHD across mmor Η barners could be prevented, the question of which donor T-cell populations are mvolved m the mduction of GVHD was largely surveyed in the murme model The T-cell subsets lmtiatmg GVHD can differ for each stram combmation (51,52) It has also been reported that the Τ cells mvolved m acute GVHD were found to be different from the clones estabhshed durmg the chromcphase of die disease (53) Although CD 8 Τ cells are often reported to be mvolved in murme GVHD modeis (50, 54), m some stram combmations CD4 Τ cells can also mediate GVHD (55, 56) Both T-cell subsets have the potential to cause GVHD (57,58) In man, the presence of a reduced number of CD4 cells in the donor marrow moculum appeared to be compatible with slow but sustamed engraftment and a low mcidence of senous acute GVHD (59) CD8 T-cell depletion m HLA-identical siblmg transplants reduces the mcidence of GVHD (60, 61) On the other hand, in vitro observed mHag-specific CTL responses did not necessarily correlate with the development of human GVHD either on the bulk or on the CTL precursor frequency level (62, 63) The same phenomenon was previously noticed in a murme GVHD model (64) and confirmed on the CTL precursor level as well (65) Several reports have demonstated the presence of anti-host mHag-specific CTLs in patients suffermg from GVHD after HLAgenotypically identical BMT (62, 66-72) Also, class IIrestricted anti-host CTLs with a CD4 phenotype were observed m a patient suffermg from severe GVHD after allogeneic BMT (24) In addition to CTLs, m vitro studies reportmg on host directed Th cells have been descnbed m patients havmg GVHD (67, 73-75) Van Eis et al (76) reported on the long-term kmetics of Th cells in response to host mHag in 16 patients and demonstrated that sigmficant Th-cell activity in vitro correlates with chnical acute GVHD These anti-host Th cells carry the CD4 phenotype and recognize mHag in the context of HLA-DR and -DP (77) Post-transplant host-directed Th-cell responses measured at the Th-cell precursor level correlate with GVHD (78) Prior to HLA-identical BMT, putative mHag-specific Th-cell precursor frequencies can be measured (79, 80) In addition to anti-host-reactive CD4 Τ cells, IL-2-secreüng CD8 Τ cells are also detected pnor to HLA-identical siblmg BMT (81) The non-Y-linked mHag -cellular recognition
Our first non-Y-lmked mHag cellularly identified on the clonal level origmated from a male acute myelogenous leukemia (AML) paüent transplanted with BM from an HLA-identical female siblmg donor His climcal recovery, however, was complicated by severe acute and chronic GVHD The initial experiment demonstrated that the post-transplant lymphocytes had strong cytotoxic activity agamst the patient's own pretransplant lymphocytes but not agamst the lymphocytes of his HLA-identical donor (66) This observation m ltself supporled the notion that, whatever the target determmant recognized by the latter CTLs, the HLA-genotypically identical donor and recipient differed for lt From additional analysis of the patient's posttransplant CTL activities, lt became apparent that the antigen (which we designated mHag HA-1) was not only present on the patient's own pretransplant cells, but could also be detected on lymphocytes from 2 out of 3 haplo-identical siblmgs, as well as on the lymphocytes of the parents and on the lymphocytes from a large number of unrelated healthy mdividuals The antigen HA-1 could be recognized by the patient's post-transplant CTLs only lf one of the patient's HLA class I antigens was present on the target cells (82) Consequently, HA-1 IS recognized in an MHC-restricted fasbion, an event comparable to the recognition of Η-Ύ With respect to our earher studies on the impact of sex mismatch in BMT, the in vitro observed CTL response in this female/male donor-recipient combmation appeared not to be directed agamst Η-Ύ Next, we aimed at both confirmation and extension of the latter results regardmg the possible impact of polymorphic genetic Systems other than HLA on the development of GVHD in man For this purpose, we mvestigated post-transplant lymphocytes from a series (N=34) of recipients of HLA-identical BM grafts for the presence of anti-host CTL activity Post-transplani lymphocytes from 21 out of 25 patients suffermg from GVHD demonstrated CTL activity which was directed agamst the patient's own pretransplant lymphocytes (83) Hostdirected CTLs could be demonstrated in 6 out of 9 patients suf fermg from acute GVHD grade 2 or more Furthermore, m 15 out of 16 patients with chronic GVHD, anti-host CTL activity was also observed lt is worth noting that such CTLs can be derived from either male or female patients suffermg from different hematologic mahgnancies pnor to BMT Similar to the initial anti-host-specific CTLs HA-1 (as discussed above), we next endeavored to uncover the specificity of the target struc tures recognized by some of the anti host CTLs (Table 4) Five (including HA-1) out of 21 anti-host CTL populations underwent comprehensive analyses at the population level as well as in famihes Comparable to HA-1, anti-host CTLs derived from the second, third, fourth and fifth patient were found to be directed agamst rnHag-designated HA-2,-3,-4 and -5, respectively, requirmg self-HLA class I antigens for their recognition These conclusions are based on the reaction patterns exhibited by CTLs HA-1 to HA-S agamst a panel of N=100 unrelated healthy mdividuals
The common denommator of HA-1-, 2-,-4-and -S-specific CTLs is the preferential use of the MHC class I restriction molecule HLA-A2 (Table 4) Whether this reflects the relatively high phenotype frequency of HLA-A2 1 (i e 49% m the Caucasian population) or suggests that HLA-A2 1 is optimally equipped to serve as the template for peptide presentation is unclear Accordmg to the latter proposition, lt is of mterest to note that allehc differences exist m the mteraction of MHC class I molecules with transporters associated with antigen processzng (84) Among other HLA alleles, HLA-A2 shows that a high affinity for TAP is required for translocation of cytosohc peptides, such as mmor Η peptides, (84a, 84b) In addiüon, however, lt is possible that TAP Supports correct folding and loadmg of a subset of MHC class I molecules (84) Table 4 also shows the results of the phenotype frequency analyses carried out for mHag HA-1 to HA-S These studies revealed that some mHag, ι e HA-1, HA-2 and HA-3, appeared frequently (69-95%), while others, ι e HA-4 and -5, occurred with lesser (7-16%) frequencies in the healthy population (85) An analysis of their genetic traits demonstrated a Mendelian mode of mhentance (Table 4 ) (86) These four antigens can each be considered as the product of a gene with one allele expressmg the detected specificity, and one or more alleles not expressmg lt Although our family data did not provide suffi cient Information concernmg lmkage between the different mH loci themselves and HLA, all our tests were compatible with the hypothesis that these Ion are mdependent of eacb other and mdependent of HLA (86) The CTL clones hsted in Table 4 were also used lo analyze functional expression (ι e (44) The additional Information on the TCR usage for recognizmg the MHC/HA-1 mHag hgand (88) will be touched upon in more detail later in this paper
In circumstances similar to ours, several other mvestigators also descnbed the cellular Identification of more (yet a rela tively small number) non-Y-lmked mHag specificities (for an overview see (89)) The charactenstics, as presented for H-Y and HA-1 lo HA-S (Table 4) , are repräsentative for other human mHag identified so far (24, 44, 71, 74, 77, 85, 86, (90) (91) (92) (93) (94) (95) (96) (97) (98) (99) (100) Table 5 summanzes the general features presently known for human mHag a) recognition by Τ cells in association with var-IOUS MHC class I and MHC class II molecules, b) occurrence with variable phenotype frequencies in the random (though HLA-restricted) population, c) segregation m a Mendelian fashion, and d) either limited or ubiquitous cell and tissue expression It is important to note that these conclusions are drawn from the outcome of functional in vitro cellular assays It is almost superfluous to State that confirmative studies on the molecular level need to be carried out
The non-Y-hnkeJ mHag -biochemical Identification Proteins of (retrc) viral, foreign or self-ongin located m ER, cytosol or any other organelle can give rise to peptides lmmunogenic to class I-restricted CTLs and can represent transplantation barners (101-105) With respect to the non-Ylmked classical mHag, the mouse maternally transmitted «mtigen (Mla) was the first one identified at the molecular level (106) This milochondrial Η antigen is a peptide derived from the amino terminus of the ND1 protein (15) Four alleles have been detected at one locus, each different by a Single amino acid (106) The first human non-Y-hnked mHag biochemically identified was HA-2 (16) The HLA-A2-bound HA-2 peptide most probably originates from an as yet unidentified member of the non-filament-formmg class I myosin family, a large family of protems that are involved in cell locomotion and organelle transport (Table 2 ) At present, we are mvestigating whether, mdeed, a class I myosm gene is the source of the HA-2 peptide Identification of the HA-2 gene will provide the basis for its differential expression in the population (Table 4 ) Its allehc polymorphism can be a result of presentation of homologous but non-identical peptides, a failure to present a peptide because it has lost its MHC-anchor residue or polymorphism in the class I antigen-processing System The amino acid sequence of the HA-1 mHag has just been elucidated as well (J Μ Μ Den Haan et al manuscript in preparation)
The non-Y-linked mHag -clinical relevance
The putative mfluence of known mHag dispanties between HLA-identical BM donors and recipients on the development of GVHD has been retrospectively analyzed Elkins et al (107) analyzed 67 pairs for mcompatibility for mHag Wl in relation to GVHD No mfluence of Wl on GVHD could be demonstrated because the number of Wl rmsmatches was too low (ι e there was a high phenotypic frequency) The study by Behar et al (108) dealt with allehc differences between donor and recipient for the polymorphic adhesion molecule CD31 CD3 1 mismatches between BM donor and recipient are associ ated with an increased nsk of severe GVHD grade 3 or 4 (P=0 004) The platelet-endothehal-cell adhesion molecule 1 (CD31) has a broad expression, and it is constitutively expressed on vascular endothehal cells, BM stem cells, platelets and leukocytes (108) Interestmgly, anti-CD31 monoclonal antibodies seemed to differentially recognize the allehc forms No CD3 1 -specific T-cell responses were reported, which sepa rates this transplantation antigen from the classical ones descnbed in man and rodents earher In a subsequent study comprising a large series of BM donor/recipient pairs, the postulated correlation between CD3 1 matches and occurrence of severe GVHD could not be confirmed (109) We analyzed the mfluence of mHag HA-1, -2, 4 and -5 mismatches between HLA-identical BM donor/recipient pairs (i e BM donor mHag-negative and BM recipient mHag-positive) on the occurrence of acute GVHD grade 2 or more The results m adult patients can be summarized as follows a mismatch for HA-1 and/or HA-2, -4, -5 was sigmficantly associ-Gouimy Minor Η antigens useful tools for marrow transplantation The fact that a significant number of BM transplants between HLA-identical sibhngs (with optimal mimunosuppression) do not lead to GVHD suggests a hierarchy in mHag immunogenicity (123) Two sets of our data are mdicative for mHag immunodominance Firstly, CTL clones reactive to the same mHag HA-1 were obtamed from peripheral blood lymphocytes of 3 mdividuals each transplanted across a multiple and probably distmct mH barner (Table 6 ) (85) for by a gene which also encodes class I CD8 T-cell epitopes (129) As discussed above (under the heading mHag-specific T-cell subsets and GVHD), lt IS hkely that both CTL and Th-cell subsets play a role m the development of human GVHD We analyzed 20 patients to determme whether anti-host CTL and Th-cell responses occurred simultaneously at different times post-HLA-identical sibhng BMT Table 8 shows anti-host CTL and Thcell responses in 10 out of 13 patients with severe GVHD On the contrary, in the "no GVHD" group of patients, both CTL and Th-cell responses were detectable m only 2 out of 7 patients analyzed These prehmmary results support the notion that CTL and Th mHag epitopes collaborate m the anti-host GVHD immune responses in man as well Naturally, ldentificaüon of the CTL and Th mHag involved m these responses needs to be determmed
T-cell repertoire dependency
Immunodommance may also depend on the available TCR repertoire Α smgle murme class I allo peptide appeared dominant in Vß8-positive but not m Vß8-negative mouse strams, mdicatmg that the dominant peptide recogmtion was dependent upon Vß8-positive Τ cells ( 1 30) We observed b^ analyzmg TCR usage of 12 clones denved from 3 mdividuals (Table 6 UPN 1, 4, S) that the TcRß rhains all used the TCRßV6S9 gene segment and showed remarkable smularities withm the N-D-N regions (Table 4) (88) Peptide affinity
One of the mechamsms of immunodommance also resides at the level of peptide/MHC-bmdmg properties The affimty of MHC class I-peptide bmding is crucial for the outcome of an immune response, even m the Situation of subdominant epitopes (131) Murme mHag T-cell responses appeared to be lnfluenced by differential bmding of the minor peptide to class I molecules (132) Usmg an equilibrium-bmdmg assay to measure relative affimties, the mHag HA-2 and the H-Y peptide are classified among the highest affimty naturally processed peptides that have been identified to date The concentration of the HA-2 peptide as competitor peptide that resulted m 50% Inhibition of the lodmated peptide binding (ICSO) was 6 7 nM, and the IC50 value for H-Y was 16 nM (Table 9) , the IC50 values for other pubhshed peptides vary from 11-214 nM for HLA-A2 (133, 134) Table 9 also ülustrates the half-maximal lysis values of the human mHag peptides HA-2 and H-Y The synthetic peptide concentrations reqmred to reconstitute 50% specific CTL recogmtion are low compared to the values of the T-cell epitopes reported earher (135) This reflects high affimty of the peptide for MHC or high affimty of the T-cell receptor
Production of cytokines
Antigen presentation by professional antigen-presentmg cells (APCs) accounts for the primary mitiation process of GVH pathogenesis Cytokines do play a sigmficant role in both acute and chronic GVHD (see (136) for a comprehensive review) In a murme model, IL-lcc has been postulated as a cntical effector molecule m mHag-directed GVHD (137) Antibodies to TNFa could completely prevent lethal GVHD mduced m mH-disparate mice (138) Also, the GVHD-mducmg potential of some mH antigen-specific T-cell clones has been shown to correlate with the levels of TNFa clones produced in vitro (139) T-cell-derived lymphokmes (IL-3, IL-4, and CSF) are produced in vivo and in vitro m response to mHag The properties of these produced activities are similar to those that responded to lrradiated syngeneic cells, but there was a difference in the time course of the lymphokme production between GVH mHag-disparate mice and the syngeneic transplant mice (140) In man, by means of a GVHD-predictive assay, the in vitro GVH reacüvity to host skm tissue was found to correlate with the levels of TNFa and INFy secreted into the supernatant of HLA-matched patient/donor mixed lymphocyte cultures (141)
Tissue distnbution
Presentation of immunogenic MHC/mH peptide complexes by Professional APCs is essential for mduction of anti-host cellular immune responses In this regard, lt is worthwhile mentiomng that the human mHag HA-1, which is shown to be sigmficantly associated with GVHD (as discussed earher), is clearly expressed on the APCs, ι e dendritic cells (DCs) and Langerhans cells (LCs) (142) The latter BM-denved APCs are most potent m mducmg alloreactive T-cell responses (143, 144) The conditionmg regime prior to BMT will ehmmate most of the recipient's hematopoietic cells, yet residual recipient cells mcludmg DCs can be present Host LCs can persist for a long time after BMT (145)
Human mHag new concepts for marrow transplantation and adoptive immunotherapy
The putative clmical potentiahty of mHag IS presently based upon in vitro results of functional and chnically related studies performed in the past Beanng this restricted Information m mmd, three areas of clmical apphcation are worthwhile mentiomng (Table 10) The Utility of diagnostics in BM donor selection is self-evident Several mHag are now biochemically identified We are currently identifying the mH genes which will provide us with the mHag allelic counterparts In the near future, molecular typmg for mHag loci can be performed Dependmg on how major the immunodominant mmors turn out to be m the HLA-matched unrelated donor/recipient combmations, one may consider overrulmg a mmor-major mismatch The speculative proposal of the use of immunodominant mHag as GVHD prophylaxis is based upon putative immunomodulation of the GVHD response with mHag peptide analogues Designmg mHag peptide analogues which function as MHC or T-cell receptor antagomsts might interfere with the harmful anü-host mHag-directed T-cell reactivities post-HLA-identical BMT The presence of human mHag peptides in non-human pnmates (42) could serve as a translational model MHC peptide antagomsts will compete for MHC binding Inhibition of secondary mixed lymphocyte reaction and prevention of murme GVHD across mH barners by high-affmity class II bmding peptides were recently demonstrated (146, 147) TCR peptide antagonists competmg by their structural similarities for TCR engagements are probably more efficient (148) Whether or not a smgle TCR antagomst can cause sigmficant Inhibition of mH-direcled T-cell responses is questionable Α major obstacle is the involvement of the vanous MHC molecules together with their respective mH allopeptides, not takmg mto account the possible subdominant mHag responses poppmg up Nonetheless, lt is worthwhile analyzmg, once the major mH protein sources are available, whether at least the harmful mH anti-host responses can be ekminated Two studies reportmg on adequate Inhibition of a CTL and a Th-cell response agamst HIV and The advantage of usmg mHag-specific CTLs as adoptive immunotherapy of leukemia lies m their restricted and specific target cell damage Thus, we will take advantage of three of the known characteristics of human mHag (Table 5) , ι e 1) MHC-restncted recogmtion by Τ cells, 2) variable phenotype frequencies, ι e mHag polymorphism, and 3) restricted tissue distribution Moreover, smce mHag are clearly expressed on circulalmg leukemic cells and rlonogenic leukemic precursor cells of both myeloid and lymphoid ongm (164, 16S), both types of leukemias can be targeted We will generate mHag peptide CTLs ex vivo from mHag-negative BM donors for mHag-positive patients Our prehmmary results are promismg We prepared peplide-specific CTL clones from an HLA-A2-posltive mHag HA-2-negaave healthy blood donor by pulsmg autologous APCs with HA-2 synthetic peptide Prohferatmg clones were expanded and tested for specific cytotoxic acuvHy agamst mHag HA-2-positive and mHag HA-2-negative EBVLCLs and HA-2-negative EBV-LCLs loaded with the HA-2 peptide and agamst mHag HA-2-positive leukemic cells The results of one mHag peptide-mduced CTL clone are shown in Fijj 2 The results are compared with those obtamed with our preexistmg (in vivo mduced) mHag HA-2-specific CTL clone assayed agamst the same target cells Upon transfusion (either pre-BMT as part of the conditionmg regimen or post-BMT as adjuvant therapy), the mHag peptide-specific CTLs will elimmate the mHag-positive patients leukemic cells and, lf of the patient's origm, also the patients hematopoietic cells but will spare the patient's non-hematopoietic cells If necessary subsequent mHag negative donor BMT will restore the patient's hematopoietic System Α universal Option would be to generate "prefab" mHag peptide-specific CTLs by usmg mHag-negative healthy blood donors with frequent HLA-homozygous haplotypes Patients who are HA-1 -or HA-2-positive (and their BM donors HA-1-or HA-2-negative) and who match the HLA typmg of the CTL donor can be treated with these "ready to be used" allo HA-1 or HA-2 peptide-specific CTLs Transduction of these CTLs with a suicide gene makes ehmmation of the CTLs possible in case adverse effects occur Future research should also focus on the possible need for mHag Th epitopes for optimal therapeutic efficacy 
